Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 6/20 | 0.50 |
| ▸ | CA2 | P00918 | 6/20 | 0.50 |
| ▸ | CA9 | Q16790 | 6/20 | 0.50 |
| ▸ | CA12 | O43570 | 5/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8647181 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL8647178 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL19477874 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL5148124 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL2338780 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL20643514 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL19477779 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL22537923 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL21762059 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL3986108 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219718-A2 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4023659-A1 | COMPOUND AND DRUG CONJUGATE, AND PREPARATION METHOD AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2022-07-06 | — | — | EP | disclosed |
| EP-3862362-A2 | CONJUGATES OF MODIFIED ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR MODULATING PKK EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3845547-A1 | GALNAC3 CONJUGATED MODIFIED OLIGONUCLEOTIDE FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| US-10883104-B2 | Compositions and methods for modulating apolipoprotein (a) expression | IONIS PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| EP-3757215-A2 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| US-10844379-B2 | Conjugated antisense compounds and their use | IONIS PHARMACEUTICALS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-10781175-B2 | Solid supports and phosphoramidite building blocks for oligonucleotide conjugates | AM CHEMICALS LLC (US) | 2020-09-22 | — | — | US | disclosed |
| EP-3690049-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| EP-3633039-A1 | COMPOSITIONS AND METHODS | Ionis Pharmaceuticals, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| WO-2019051257-A2 | METHODS FOR TREATING HEPATITIS B INFECTIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-03-14 | — | — | WO | disclosed |
| US-20180016232-A1 | SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE CONJUGATES | AM CHEMICALS LLC (US) | 2018-01-18 | — | — | US | disclosed |
| WO-2017177326-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2017-10-19 | — | — | WO | disclosed |
| WO-2015168514-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| US-9150602-B2 | Precursor used for labeling hepatorcyte receptor and containing trisaccharide and diamide demercaptide ligand, method for preparing the same, radiotracer and pharmaceutical composition of the same | ATOMIC ENERGY COUNCIL, INSTITUTE OF NUCLEAR ENERGY RESEARCH (TW) | 2015-10-06 | — | — | US | disclosed |
| WO-2015006740-A2 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
| WO-2014179627-A2 | COMPOSITIONS AND METHODS FOR MODULATING HBV AND TTR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| US-20140031533-A1 | PRECURSOR USED FOR LABELING HEPATORCYTE RECEPTOR AND CONTAINING TRISACCHARIDE AND DIAMIDE DEMERCAPTIDE LIGAND, METHOD FOR PREPARING THE SAME, RADIOTRACER AND PHARMACEUTICAL COMPOSITION OF THE SAME | ATOMIC ENERGY COUNCIL, INSTITUTE OF NUCLEAR ENERGY RESEARCH (TW) | 2014-01-30 | — | — | US | disclosed |
| US-8551447-B2 | Bifunctional compound with monosaccharide and N2S2 ligand, and preparation and use thereof | INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN (TW) | 2013-10-08 | — | — | US | disclosed |
| US-20120009669-A1 | BIFUNCTIONAL COMPOUND WITH MONOSACCHARIDE AND N2S2 LIGAND, AND PREPARATION AND USE THEREOF | INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN (TW) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781175-B2 | Solid supports and phosphoramidite building blocks for oligonucleotide conjugates | NCL, PAICS, RTCB | LMNA 2437/4885KMT2A 1607/4885POLB 14/4885 |
| US-20120009669-A1 | BIFUNCTIONAL COMPOUND WITH MONOSACCHARIDE AND N2S2 LIGAND, AND PREPARATION AND USE THEREOF | B3GNT2, FUT5, FUT6 | LMNA 2601/4885KMT2A 3100/4885POLB 4683/4885 |
| US-10883104-B2 | Compositions and methods for modulating apolipoprotein (a) expression | APOB, APOL1, LDLR | LMNA 158/4885KMT2A 2375/4885POLB 3193/4885 |
| US-20140031533-A1 | PRECURSOR USED FOR LABELING HEPATORCYTE RECEPTOR AND CONTAINING TRISACCHARIDE AND DIAMIDE DEMERCAPTIDE LIGAND, METHOD FOR PREPARING THE SAME, RADIOTRACER AND PHARMACEUTICAL COMPOSITION OF THE SAME | ASGR1, M6PR, DDOST | LMNA 4135/4885KMT2A 4410/4885POLB 4829/4885 |
| US-10844379-B2 | Conjugated antisense compounds and their use | CSGALNACT1, GALNT1, GALNT6 | LMNA 595/4885KMT2A 1580/4885POLB 416/4885 |
| US-20180016232-A1 | SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE CONJUGATES | NCL, PAICS, RTCB | LMNA 2437/4885KMT2A 1607/4885POLB 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.